uploads/2018/12/medic-563423_1280.jpg

Why Clovis Oncology Stock Rose 48% in November

By

Updated

Stock performance

On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30. Clovis Oncology’s stock price grew from $11.63 at the close of business on October 31 to $17.21 at the close of the market on November 30, which reflects ~48% growth in November.

On December 3, Clovis Oncology stock closed at $19.08, which is an ~72% decline from its 52-week high of $69.02 on December 29, 2017. After the company hit its 52-week low of $11.50 on October 31, the stock witnessed solid growth in November.

Article continues below advertisement

Reasons for the stock hike

Clovis Oncology’s stock price rose in November after the company released its third-quarter financial results on October 30. Clovis Oncology reported net revenues of $22.8 million in the third quarter, which reflects ~35% YoY (year-over-year) growth. Clovis Oncology’s revenues are mainly from Rubraca’s sales.

In the third quarter, Clovis Oncology’s peers in the biopharmaceuticals market, Puma Biotechnology (PBYI), Exelixis (EXEL), and Tesaro (TSRO) generated revenues of $62.6 million, $225.4 million, and $64.40 million, respectively—compared to $6.1 million, $152.5 million, and $142.77 million in the third quarter of 2017.

Clovis Oncology, Puma Biotechnology, Exelixis, and Tesaro’s revenue growth could boost the SPDR S&P Biotech ETF’s (XBI) shares prices. The companies account for ~2.93%, ~2.97%, ~2.61%, and ~3.08% of XBI’s total portfolio holdings.

The company’s net operating expenses during the first nine months of 2018 amounted to $301.9 million—compared to $212.9 million during the same period in 2017.

Clovis Oncology’s net income and diluted EPS during the first nine months of 2018 amounted to -$268.8 million and -$5.18, respectively, compared to -$294.5 million and -$6.39 during the same period in 2017.

Analysts’ recommendations

Among the 12 analysts tracking Clovis Oncology in December, two recommended a “strong buy,” five recommended a “buy,” and five recommended a “hold” in December.

On December 4, Clovis Oncology had a consensus 12-month target price of $23.7, which represents an ~24.21% return on investment over the next 12 months.

Advertisement

More From Market Realist